64 related articles for article (PubMed ID: 8131340)
1. Inflammatory cells in the pseudocapsule of osteosarcoma. A clinicopathologic analysis.
Miura Y; Suda A; Watanabe Y; Yamakawa M; Imai Y
Clin Orthop Relat Res; 1994 Mar; (300):225-32. PubMed ID: 8131340
[TBL] [Abstract][Full Text] [Related]
2. Comparison of histological changes and changes in nm23 and c-MET expression between primary and metastatic sites in osteosarcoma: a clinicopathologic and immunohistochemical study.
Oda Y; Naka T; Takeshita M; Iwamoto Y; Tsuneyoshi M
Hum Pathol; 2000 Jun; 31(6):709-16. PubMed ID: 10872665
[TBL] [Abstract][Full Text] [Related]
3. Hematogenous micrometastases in osteosarcoma patients.
Bruland OS; Høifødt H; Saeter G; Smeland S; Fodstad O
Clin Cancer Res; 2005 Jul; 11(13):4666-73. PubMed ID: 16000559
[TBL] [Abstract][Full Text] [Related]
4. Characterization of osteosarcoma cell lines MG-63, Saos-2 and U-2 OS in comparison to human osteoblasts.
Pautke C; Schieker M; Tischer T; Kolk A; Neth P; Mutschler W; Milz S
Anticancer Res; 2004; 24(6):3743-8. PubMed ID: 15736406
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of hypoxia-inducible factor-1alpha in human osteosarcoma: correlation with clinicopathological parameters and survival outcome.
Yang QC; Zeng BF; Dong Y; Shi ZM; Jiang ZM; Huang J
Jpn J Clin Oncol; 2007 Feb; 37(2):127-34. PubMed ID: 17237146
[TBL] [Abstract][Full Text] [Related]
6. Evaluating marrow margins for resection of osteosarcoma. A modern approach.
Meyer MS; Spanier SS; Moser M; Scarborough MT
Clin Orthop Relat Res; 1999 Jun; (363):170-5. PubMed ID: 10379319
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of immunohistochemical expression of ezrin in non-metastatic high-grade osteosarcoma.
Ferrari S; Zanella L; Alberghini M; Palmerini E; Staals E; Bacchini P
Pediatr Blood Cancer; 2008 Apr; 50(4):752-6. PubMed ID: 17886294
[TBL] [Abstract][Full Text] [Related]
8. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS).
Kempf-Bielack B; Bielack SS; Jürgens H; Branscheid D; Berdel WE; Exner GU; Göbel U; Helmke K; Jundt G; Kabisch H; Kevric M; Klingebiel T; Kotz R; Maas R; Schwarz R; Semik M; Treuner J; Zoubek A; Winkler K
J Clin Oncol; 2005 Jan; 23(3):559-68. PubMed ID: 15659502
[TBL] [Abstract][Full Text] [Related]
9. Ezrin expression predicts survival in stage IIB osteosarcomas.
Kim MS; Song WS; Cho WH; Lee SY; Jeon DG
Clin Orthop Relat Res; 2007 Jun; 459():229-36. PubMed ID: 17353802
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of membrane-type matrix metalloproteinase-1 is correlated with poor prognosis in patients with osteosarcoma.
Uchibori M; Nishida Y; Nagasaka T; Yamada Y; Nakanishi K; Ishiguro N
Int J Oncol; 2006 Jan; 28(1):33-42. PubMed ID: 16327977
[TBL] [Abstract][Full Text] [Related]
11. Expression of osteopontin and vascular endothelial growth factor in benign and malignant bone tumors.
Sulzbacher I; Birner P; Trieb K; Lang S; Chott A
Virchows Arch; 2002 Oct; 441(4):345-9. PubMed ID: 12404059
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical profile of ephrin A4 expression in human osteosarcoma.
Abdou AG; Abd El-Wahed MM; Asaad NY; Samaka RM; Abdallaha R
APMIS; 2009 Apr; 117(4):277-85. PubMed ID: 19338516
[TBL] [Abstract][Full Text] [Related]
13. Cyto-histological correlations in primary, recurrent, and metastatic bone and soft tissue osteosarcoma. Institut Curie's experience.
Klijanienko J; Caillaud JM; Orbach D; Brisse H; Lagacé R; Sastre-Gareau X
Diagn Cytopathol; 2007 May; 35(5):270-5. PubMed ID: 17427216
[TBL] [Abstract][Full Text] [Related]
14. Expression of vascular endothelial growth factor-C and its receptor in osteosarcomas.
Park HR; Min K; Kim HS; Jung WW; Park YK
Pathol Res Pract; 2008; 204(8):575-82. PubMed ID: 18440723
[TBL] [Abstract][Full Text] [Related]
15. Ultrastructure of low-grade intraosseous osteosarcoma of bone: a comparative study with fibrous dysplasia and parosteal osteosarcoma.
Steiner GC; Forest M; Vacher-Lavenu MC
Ultrastruct Pathol; 2006; 30(4):293-9. PubMed ID: 16971354
[TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis rate adjusted by tumor volume change is a better predictor of survival of localized osteosarcoma patients.
Kim MS; Lee SY; Cho WH; Song WS; Koh JS; Lee JA; Yoo JY; Jeon DG
Ann Surg Oncol; 2008 Mar; 15(3):906-14. PubMed ID: 18163171
[TBL] [Abstract][Full Text] [Related]
17. Quantitative analysis of promoter hypermethylation in multiple genes in osteosarcoma.
Hou P; Ji M; Yang B; Chen Z; Qiu J; Shi X; Lu Z
Cancer; 2006 Apr; 106(7):1602-9. PubMed ID: 16502411
[TBL] [Abstract][Full Text] [Related]
18. [Diagnosis and surgical treatment of metastatic lung tumors].
Yamamoto Y; Hirata T; Fukuse T; Yokomise H; Ike O; Mizuno H; Wada H; Hitomi S; Nakamura T; Shimizu Y
Gan To Kagaku Ryoho; 1996 Sep; 23(10):1248-54. PubMed ID: 8831735
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution.
Bacci G; Longhi A; Versari M; Mercuri M; Briccoli A; Picci P
Cancer; 2006 Mar; 106(5):1154-61. PubMed ID: 16421923
[TBL] [Abstract][Full Text] [Related]
20. Growth patterns of osteosarcoma predict patient survival.
Kim MS; Lee SY; Cho WH; Song WS; Koh JS; Lee JA; Yoo JY; Shin DS; Jeon DG
Arch Orthop Trauma Surg; 2009 Sep; 129(9):1189-96. PubMed ID: 18682966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
